image description

Tag: Plaquenil

COVID-19 Frequently Asked Questions: What You Should Know

Updated April 3, 2020 The first priority of the Lupus Research Alliance is the health of our lupus community.  We have been consulting with health care authorities and monitoring the situation created by the spread of COVID-19. Please note that every lupus patient is different. If you have specific questions about your condition and/or any […] Read More

MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community

March 26, 2020 The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch rapidly changing developments regarding COVID-19 and is closely monitoring the policies and actions of the federal government, healthcare agencies, medical organizations and the pharmaceutical industry on behalf of people with lupus. Thrust into the spotlight […] Read More

LRA Sponsors COVID-19 Global Rheumatology Alliance

March 25, 2020 LRA Sponsors COVID-19 Global Rheumatology Alliance The LRA is proud to be among the sponsors of the COVID-19 Global Rheumatology Alliance, a grassroots group led by rheumatologists and uniting rheumatologists and patients with rheumatic diseases worldwide to respond to the global pandemic. In concert with the American College of Rheumatology, the group’s […] Read More

Hydroxychloroquine: Common Lupus Drug in Testing for COVID-19

March 19, 2020 In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found to cause a severe respiratory illness in patients which was later named after the type of virus that caused it and the year it was identified (coronavirus disease 2019 or COVID-19)1 Currently there is no […] Read More

Potential New Lupus Treatment Outperforms Hydroxychloroquine in Animal Study

November 28, 2018 Anti-malaria drugs such as hydroxychloroquine are common treatments for arthritis and heat rash in patients with lupus. A new study by Target Identification in Lupus grantee Keith Elkon, MD, of the University of Washington, Seattle, and colleagues suggests that a new drug they designed works better than the commonly prescribed hydroxychloroquine in […] Read More